Trial watch: Naked and vectored DNA-based anticancer vaccines Academic Article uri icon


MeSH Major

  • Autophagy
  • Biological Assay


  • One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is to drive the synthesis of TAAs in the context of an immunostimulatory milieu, resulting in the (re-)elicitation of a tumor-targeting immune response. In spite of encouraging preclinical results, the clinical efficacy of DNA-based vaccines employed as standalone immunotherapeutic interventions in cancer patients appears to be limited. Thus, efforts are currently being devoted to the development of combinatorial regimens that allow DNA-based anticancer vaccines to elicit clinically relevant immune responses. Here, we discuss recent advances in the preclinical and clinical development of this therapeutic paradigm.

publication date

  • January 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC4485755

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2015.1026531

PubMed ID

  • 26155408

Additional Document Info

start page

  • e1026531


  • 4


  • 5